Search
for
Sort by
Research 751–780 of 1000+
- Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
- Long-term experiences with minoxidil in combination treatment of severe arterial hypertension.
- Hyperpigmentation, severe alopecia, and six days of instability in a case of severe methotrexate hypersensitivity reaction
- Psoriasiform Lesions and Abscesses as Initial Manifestations of Severe Hypothyroidism in a Previously Healthy 15‐Year‐Old Girl
- Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata
- Clinical experience on follicular unit extraction megasession for severe androgenetic alopecia
- Excimer lamp as an effective alternative treatment for severe alopecia areata
- Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period
- Kerion celsi due to <i>Microsporum audouinii</i>: a severe form in an immunocompetent girl
- Missense mutation Y449H of the K10 gene in a patient with severe epidermolytic ichthyosis
- Adalimumab improves health-related quality of life (HRQoL) in patients with moderate to severe hidradenitis suppurativa (HS): Results from the first 12 weeks of PIONEER II
- Predominance of CD27-PD-1- Effector Memory T Cells Re-Expressing CD45RA Characterizes Treatment-Resistant Severe Alopecia Areata
- Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Unravelling Beau's lines as a potential indicator of severe immune response in COVID-19 and reinfection
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
- Microneedling combined with compound betamethasone in treatment of severe alopecia areata: A case report
- A response to “Male balding is a major risk factor for severe COVID-19”
- Depression Risk in the Treatment of Moderate to Severe Acne with Isotretinoin
- [Mycophenolate mofetil in induction and maintenance therapy for juvenile onset severe lupus nephritis].
- Oral Tofacitinib for the Management of Moderate to Severe Alopecia Areata in Children and Adolescents: A Retrospective Study of 36 Patients
- 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials
- 43927 The Impact of Treatment with Guselkumab on Skin-related Quality of Life in Male and Female Patients with Moderate to Severe Psoriasis: Results from the VOYAGE 1 and 2 Trials
- 40062 Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study
- Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata